title: [Naturally occurring oseltamivir resistance in influenza A].
abstract: During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option. The virus does, however, remain sensitive to zanamavir and amantadine. There is no unequivocal explanation for this slide in the development of resistance. The best prevention strategy remains vaccination of the general population to avoid immunity. Future antiviral treatment calls for knowledge about resistance to existing types of influenza and the availability of all three types of antiviral medication.
authors.affiliation: Rigshospitalet, Klinisk Mikrobiologisk Afdeling, og Københavns Universitet, Det Sundhedsvidenskabelige Fakultet, Denmark.
authors.forename: Laura
authors.initials: L
authors.lastname: Madsen
authors.forename: Alex
authors.initials: A
authors.lastname: Nielsen
authors.forename: Jens
authors.initials: J
authors.lastname: Lundgren
mesh_terms: D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics / Q000276:immunology; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage; D007251:Influenza, Human / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D009154:Mutation; D009439:Neuraminidase / Q000235:genetics; D053139:Oseltamivir / Q000627:therapeutic use*; D053243:Zanamivir / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D007252:Influenza Vaccines; D053139:Oseltamivir; D000547:Amantadine; D009439:Neuraminidase; D053243:Zanamivir